AXON - Axovant Sciences Ltd.
| Previous Close | 1.22 |
| Open | 1.21 |
| Bid | 1.25 x 1300 |
| Ask | 1.26 x 1000 |
| Day's Range | 1.20 - 1.27 |
| 52 Week Range | 1.02 - 27.98 |
| Volume | 204,784 |
| Avg. Volume | 695,167 |
| Market Cap | 135.813M |
| Beta | -0.40 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.37 |
| Earnings Date | Nov 6, 2017 - Nov 10, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.14 |
- Fortune•26 days ago
Police Body Cameras Could Get Facial Recognition Technology
The move has already been met with opposition.
Markit•last monthSee what the IHS Markit Score report has to say about Axovant Sciences Ltd.
Axovant Sciences Ltd NASDAQ/NGS:AXON
- Benzinga•2 months ago
Pair Trade Closed: Chardan No Longer Advocates Owning vTv Therapeutics Over Axovant
vTv Therapeutics Inc (NASDAQ: VTVT ) shares have outperformed Axovant Sciences Ltd (NASDAQ: AXON ) shares by 63 percent since Chardan recommended owning the former over the latter in January 2016. The ...
Markit•2 months agoSee what the IHS Markit Score report has to say about Axovant Sciences Ltd.
Axovant Sciences Ltd NASDAQ/NGS:AXON
Markit•3 months agoSee what the IHS Markit Score report has to say about Axovant Sciences Ltd.
Axovant Sciences Ltd NASDAQ/NGS:AXON
- Zacks•3 months ago
Options Traders Expect Huge Moves in Axovant Sciences (AXON) Stock
Surging implied volatility makes Axovant Sciences (AXON) stock lucrative to the option traders.
- Business Wire•3 months ago
AXON INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Axovant Sciences Ltd. Investors
Law Offices of Howard G. Smith commences an investigation on behalf of Axovant Sciences Ltd. investors concerning the Company and its officers’ possible violations of federal securities laws.
Markit•3 months agoSee what the IHS Markit Score report has to say about Axovant Sciences Ltd.
Axovant Sciences Ltd NASDAQ/NGS:AXON
- Reuters•3 months ago
Axovant Sciences CEO David Hung resigns, shares tumble
Axovant Chief Operating Officer Marion McCourt and three directors on the company's board also stepped down. The departures come after Axovant stopped developing its lead drug, intepirdine, following the failure of two trials testing it as a treatment for Alzheimer's disease and dementia. "There is plenty of work to be done," incoming Axovant CEO Pavan Cheruvu said on a call with analysts.
- TheStreet.com•3 months ago
Axovant Shares Crater as CEO and President Both Resign
Chief executive David Hung resigned from the Basel, Switzerland, biotech after just 10 months on the job.
Markit•3 months agoSee what the IHS Markit Score report has to say about Axovant Sciences Ltd.
Axovant Sciences Ltd NASDAQ/NGS:AXON
- TheStreet.com•4 months ago
Five Rules for This Market Beast: Cramer's 'Mad Money' Recap (Tues 1/16/18)
Even with Monday's sharp reversal, Jim Cramer says he still likes this market.
- Benzinga•4 months ago
After A Freefall In Axovant Shares, Chardan Upgrades
Axovant Sciences Ltd (NASDAQ: AXON )'s announcement this week that its lead drug candidate intepirdine failed in a late-stage trial comes after the stock lost 90 percent of its value over the past three ...
- Zacks•4 months ago
Implied Volatility Surging for Axovant Sciences (AXON) Stock Options
Surging implied volatility makes Axovant Sciences (AXON) stock lucrative to the option traders.
- Zacks•4 months ago
Biotech Stock Roundup: Celgene to Acquire Impact, J.P. Morgan Healthcare Conference in Focus
Focus this week was on preliminary results and 2018 outlooks provided by several companies including Celgene (CELG) at a healthcare conference.
Markit•4 months agoSee what the IHS Markit Score report has to say about Axovant Sciences Ltd.
Short interest is low for AXON with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.
- Motley Fool•4 months ago
Why Dave & Buster's Entertainment, Axovant Sciences, and Five Below Slumped Today
Even on another solid market day, these stocks fell. Find out why.
- American City Business Journals•4 months ago
Roivant-backed company partners with DCRI
Roivant-backed health care technology company Datavant – formed late last year – has landed its first academic partner in Duke Clinical Research Institute (DCRI). Since the rollout of Datavant – on the heels of Roivant landing a $1.1 billion equity investment led by SoftBank Vision Fund – Datavant has integrated 150 datasets, aimed at using artificial intelligence to improve the time and success of clinical trials as well as their costs. "As I was founding Datavant, one of the first members of our advisory board was Frank Rockhold, a tireless advocate of clinical data sharing and a professor of biostatistics and bioinformatics at DCRI. Soon after meeting with other members of the DCRI leadership we each recognized the strong fit between our organizations and the potential for a partnership that would transform the drug development process,” Travis May, president and co-founder of Datavant, said in an email.
- Motley Fool•4 months ago
Here's Why Axovant Sciences Dropped Today
The company's future is in serious doubt.
